News | May 26, 2025
Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
There was no observation related to data integrity reported
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
